Holen Sie sich die Stockscreener-App
1.655
2.36%
-0.04
Handel nachbörslich:
1.66
0.005
+0.30%
Schlusskurs vom Vortag:
$1.695
Offen:
$1.74
24-Stunden-Volumen:
267.37K
Relative Volume:
0.41
Marktkapitalisierung:
$208.62M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-35.47M
KGV:
-3.0911
EPS:
-0.5354
Netto-Cashflow:
$-124.27M
1W Leistung:
-23.02%
1M Leistung:
-15.99%
6M Leistung:
-59.19%
1J Leistung:
+36.78%
1-Tages-Spanne:
$1.615
$1.775
1-Wochen-Bereich:
$1.615
$2.265
52-Wochen-Spanne:
$1.18
$4.44
Prokidney Corp Stock (PROK) Company Profile
Firmenname
Prokidney Corp
Sektor
Branche
Telefon
336-999-7028
Adresse
2000 FRONTIS PLAZA BLVD., WINSTON-SALEM
Vergleichen Sie PROK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| PROK | 1.655 | 208.62M | 0 | -35.47M | -124.27M | -0.5354 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Prokidney Corp Stock (PROK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-21 | Eingeleitet | Jefferies | Buy |
| 2022-11-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-18 | Eingeleitet | UBS | Buy |
| 2022-10-14 | Eingeleitet | Citigroup | Buy |
| 2022-09-23 | Eingeleitet | BofA Securities | Buy |
| 2022-09-02 | Eingeleitet | Evercore ISI | Outperform |
Alle ansehen
Prokidney Corp Aktie (PROK) Neueste Nachrichten
ProKidney lists building where it planned $458M investment for sale - The Business Journals
We're Hopeful That ProKidney (NASDAQ:PROK) Will Use Its Cash Wisely - Simply Wall St
ProKidney’s Progress in FDA Approval and Financial Health - TipRanks
Prokidney Corp. Reports Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - Marketscreener.com
ProKidney Reports Third Quarter 2024 Financial Results along with Regulatory and Clinical Development Updates Following Successful FDA Type B Meeting - The Manila Times
ProKidney Reports Third Quarter 2024 Financial Results - GlobeNewswire
ProKidney Surges on FDA Backing for Phase 3 Study, Reports $406.8M Cash Position | PROK Stock News - StockTitan
Triad's public companies have gained millions in value since election - The Business Journals
Morgan Stanley's Strategic Reduction in ProKidney Corp Holdings - GuruFocus.com
ProKidney: Major Catalyst Is Too Far Away (NASDAQ:PROK) - Seeking Alpha
ProKidney to Participate in the Guggenheim Inaugural - GlobeNewswire
ProKidney (PROK) to Present at Guggenheim and Jefferies Healthcare Conferences | PROK Stock News - StockTitan
ProKidney amends Phase III protocol in light of Phase II results - MSN
Head to Head Review: ProKidney (NASDAQ:PROK) vs. TScan Therapeutics (NASDAQ:TCRX) - Defense World
ProKidney CEO Bruce Culleton named to Triad Power 50 Five to Watch list - The Business Journals
Suvretta Capital Management's Strategic Acquisition in ProKidney Corp - Yahoo Finance
Reviewing ProKidney (NASDAQ:PROK) and Innate Pharma (NASDAQ:IPHA) - Defense World
We're Not Very Worried About ProKidney's (NASDAQ:PROK) Cash Burn Rate - Yahoo Finance
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2024 - The Manila Times
ProKidney Announces Five Abstracts Selected for - GlobeNewswire
ProKidney Announces Five Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2024 - Yahoo Finance
Stocks of ProKidney Corp (PROK) are poised to climb above their peers - SETE News
Gaining Ground: ProKidney Corp (PROK) Closes Lower at 1.70, Down -0.58 - The Dwinnex
PROK underperforms with a -1.16 decrease in share price - US Post News
ProKidney Corp (PROK) Becoming More Attractive for Investors - Knox Daily
PROK’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle
ProKidney to Participate in the UBS Virtual Organ Restoration Day - GlobeNewswire
ProKidney Corp [PROK] Records 50-Day SMA of $2.2292 - Knox Daily
A History of Outperforming Analyst Forecasts and Beating the Odds: ProKidney Corp (PROK) - SETE News
ProKidney Corp (PROK) deserves deeper analysis - US Post News
Recent Insider Activity Suggests Potential Gains for ProKidney Corp (PROK) - Knox Daily
JPMorgan Chase & Co. Initiates Coverage on ProKidney (NASDAQ:PROK) - MarketBeat
An In-Depth Look at ProKidney Corp Inc. (PROK) Price Performance During Market Crashes - The InvestChronicle
ProKidney Corp (PROK)’s Day in Review: Closing at 1.86, Down by -8.82 - The Dwinnex
JPMorgan starts ProKidney stock coverage with Neutral rating - Investing.com
How does ProKidney Corp (PROK) change from a tortoise to a hare? - SETE News
Insider Selling: Weber Darin J., ProKidney Corp [PROK] Chief Regulatory Officer divested 16,412 shares - Knox Daily
Insiders Re-Evaluate Their US$54.7m Stock Purchase As ProKidney Falls To US$659m - Simply Wall St
ProKidney Corp (PROK) Stock: Uncovering a 52-Week Range and Trading Volume - The InvestChronicle
Is it possible to buy ProKidney Corp(PROK) shares at a good price now? - US Post News
Examining the Potential Price Growth of ProKidney Corp (PROK) - Knox Daily
Investor’s Toolkit: Key Ratios for Assessing ProKidney Corp (PROK)’s Performance - The Dwinnex
ProKidney revises Phase 3 program for lead asset - MSN
Reviewing LadRx (OTCMKTS:CYTR) and ProKidney (NASDAQ:PROK) - Defense World
ProKidney (NASDAQ:PROK) Sees Unusually-High Trading Volume - Defense World
ProKidney executive sells $41,030 in company stock By Investing.com - Investing.com Australia
ProKidney Corp. (NASDAQ:PROK) Insider Darin J. Weber Sells 16,412 Shares - MarketBeat
ProKidney executive sells $41,030 in company stock - Investing.com India
ProKidney (NASDAQ:PROK) Shares Down 6.7% - MarketBeat
Propel Hits 52-Week High on KOHO Link - Baystreet.ca
Propel Holdings Inc. - Baystreet.ca
Finanzdaten der Prokidney Corp-Aktie (PROK)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.66%
1.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):